scholarly article | Q13442814 |
P356 | DOI | 10.1136/HEARTJNL-2015-308963 |
P698 | PubMed publication ID | 26848185 |
P50 | author | Steen E Husted | Q114427074 |
Jérémie Abtan | Q114427161 | ||
Lars Wallentin | Q6230815 | ||
Philippe Gabriel Steg | Q16027739 | ||
Hugo A. Katus | Q27929168 | ||
Robert F. Storey | Q38590637 | ||
Robert A Harrington | Q62914910 | ||
Anne S Hellkamp | Q63019876 | ||
Dominick Angiolillo | Q72837721 | ||
Stefan James | Q86735199 | ||
Matthijs In 't Veld | Q87658927 | ||
Diego Ardissino | Q91861722 | ||
Phillip J Schulte | Q114336769 | ||
Anders Himmelmann | Q114371164 | ||
PLATO Investigators | Q114371185 | ||
P2093 | author name string | Bernhard Meier | |
P2860 | cites work | ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) | Q22242892 |
Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction | Q22242900 | ||
Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
Representation of elderly persons and women in published randomized trials of acute coronary syndromes | Q34331421 | ||
Clinical end points in coronary stent trials: a case for standardized definitions | Q36807166 | ||
Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review | Q37292941 | ||
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis | Q38071527 | ||
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction | Q38460956 | ||
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis | Q38497913 | ||
Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb-IIIa facilitated primary angioplasty (from the EGYPT cooperation). | Q38966136 | ||
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials | Q41187186 | ||
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy | Q42910350 | ||
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q44265041 | ||
Door-to-balloon time and mortality among patients undergoing primary PCI. | Q44655278 | ||
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) tria | Q46068914 | ||
Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Inves | Q52914499 | ||
Prehospital ticagrelor in ST-segment elevation myocardial infarction. | Q53084786 | ||
Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction | Q56944163 | ||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | clopidogrel | Q410237 |
P304 | page(s) | 617-625 | |
P577 | publication date | 2016-02-04 | |
P1433 | published in | Heart | Q856338 |
P1476 | title | Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention | |
P478 | volume | 102 |
Q55287536 | A Case of Atrioventricular Block Potentially Associated with Right Coronary Artery Lesion and Ticagrelor Therapy Mediated by the Increasing Adenosine Plasma Concentration. |
Q39147735 | Antithrombotic therapy for patients with STEMI undergoing primary PCI. |
Q49926557 | Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives |
Q91864154 | Changing Paradigms of Periprocedural Antithrombotic Therapy in Neuroendovascular Therapy: Analysis of JR-NET 3 |
Q55396201 | Comparative Review of Oral P2Y12 Inhibitors. |
Q47744395 | Comparison of treatment outcomes of ticagrelor and clopidogrel among patients undergoing percutaneous coronary intervention: A meta-analysis |
Q90464083 | Continuum of Care for Acute Coronary Syndrome: Optimizing Treatment for ST-Elevation Myocardial Infarction and Non-St-Elevation Acute Coronary Syndrome |
Q38855389 | Current and novel approaches to treat patients presenting with ST elevation myocardial infarction |
Q57143053 | De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention |
Q64284677 | Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial |
Q92990016 | Impact of Preadmission Morphine on Reinfarction in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention: A Meta-Analysis |
Q89563788 | LMU Munich: platelet inhibition novel aspects on platelet inhibition and function |
Q41628280 | Pharmacokinetics and relative bioavailability of fixed-dose combination of clopidogrel and aspirin versus coadministration of individual formulations in healthy Korean men. |
Q48512017 | Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets |
Search more.